

## Original Article

# Computed Tomography and Clinical Features for Diagnosis of COVID-19 Pneumonia and Differentiating from Common Viral Pneumonia

Suresh Jat<sup>1</sup>, Omprakash<sup>2</sup>, Reena Mathur<sup>3</sup>, Avinash Gupta<sup>4</sup>, Rachitha N<sup>5</sup>,  
Cremica Gupta<sup>6</sup>, Devraj Yadav<sup>7</sup>

<sup>1,2,5,6</sup>Resident, <sup>3</sup>Senior Professor and Head, <sup>4</sup>Senior Professor, <sup>7</sup>Assistant Professor, Department of Radiodiagnosis, JLN Medical College and Associated Group of Hospitals, Ajmer, Rajasthan, India

DOI:10.37821/ruhsjhs.7.3.2022.413



This is an open-access article distributed under the terms of Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International License (CC BY-NC-ND) (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

## ABSTRACT

**Introduction:** HRCT chest has high sensitivity in diagnosis of corona virus disease 2019 (COVID-19) in a screening population, but it is thought to be nonspecific. The study aimed to determine the predictive features of computed tomography (CT) and clinical features for diagnosing COVID-19 pneumonia and differentiating it from non-COVID-19 viral pneumonia.

**Methodology:** A retrospective study was done on 21 patients with confirmed COVID-19 pneumonia (group 1). In addition, 16 patients with confirmed cases of other common viral pneumonia (group 2) during the first and second wave to analyse characteristics of COVID-19 pneumonia were included in the study. Patients with laboratory confirmed RTPCR test positive and undergone CT scan were included.

**Results:** The factors including size of ground glass opacity (GGO), GGO with reticular and/or interlobular septal thickening, vascular enlargement, “tree-in-bud” opacity, centrilobular nodules, and stuffy or runny nose were associated with group 2 (COVID-19) of viral pneumonia. Only GGO with reticular and/or interlobular septal thickening, centrilobular nodules, and stuffy or runny nose remained independent risk factors in multinomial logistic regression analysis for COVID-19 pneumonia.

**Conclusion:** GGO with reticular and/or interlobular septal thickening, absence of centrilobular nodules on computed tomography, and absence of stuffy or runny nose are presented in patients with COVID-19 pneumonia.

**Keywords:** Computed tomography, COVID-19 pneumonia, Ground glass opacities.

## INTRODUCTION

The disease infected by *SARS-CoV-2* was named COVID-19 by the World Health Organization (WHO) on January 12, 2020.<sup>1,2</sup> Since the outbreak of COVID-19, the transmission among people was quick. Early diagnosis and early treatment are crucial for successful treatment and prevention of transmission. The sensitivity of *SARS-CoV-2* nucleic acid detection is poor. COVID-19 mainly affects the lungs. According to current experience, thin-section CT is objective and sensitive for screening the COVID-19 pneumonia.<sup>1</sup>

With the emergence of COVID-19 cases during the influenza season, an accurate differentiation of COVID-19 pneumonia from common viral pneumonia is crucial and decreases the cost of treatment.<sup>3-10</sup> However, most viral pneumonia patterns exhibit similarity of CT findings.<sup>11-14</sup> When taken with clinical symptoms, the diagnostic yield should be much higher in differentiating COVID-19 pneumonia from other viral pneumonias. Furthermore, investigation regarding the imaging and clinical differentiation of COVID-19 pneumonia from common viral pneumonia is lacking.

In this study, we retrospectively reviewed the CT findings and clinical data of patients with COVID-19 pneumonia and common viral pneumonia to identify the predictive features for differential diagnosis. Previous studies have not directly compared chest CT patterns of COVID-19 with those of common viral pneumonia at chest CT. The purpose of this study was to assess the performance of CT findings in differentiating COVID-19 from non-COVID-19 common viral pneumonia in chest HRCT.

## METHODS

A retrospective study was carried out on 21 confirmed COVID-19 pneumonia patients. In addition, 16 patients with confirmed other common viral pneumonia in first and second wave were included to analyse characteristics of COVID-19 pneumonia.

Inclusion criteria of COVID-19 pneumonia were patients with laboratory confirmed COVID-19 and patients with thin section chest CT examination who demonstrated pneumonia.

The criteria of common viral pneumonia were patients with laboratory confirmed pneumonia infected by other viruses (*respiratory syncytial virus, adenovirus, and influenza virus*) and were negative *SARS-CoV-2* during the outbreak of COVID-19. A review of clinical data including age, sex, white blood cell (WBC) count, and lymphocyte (LYM) count, fever, dry cough, stuffy or runny nose, headache, sore throat, fatigue, myalgia, and diarrhoea was done.

Computed tomography imaging was performed in all patients using a 16-slice spiral CT (Philips MX-16). The imaging parameters were 120 KV, 150 to 300 mA of automatic adjustment, a pitch of 1.5, 0.625 mm of collimation, 512×512 of matrix. Axial and coronal multiplanar reconstruction images with 1 to 5 mm thick were obtained with lung or mediastinum windows.

**Imaging Analysis:** Two experienced radiologists reviewed the CT scan data independently. Computed tomography imaging features like lesion involvement, number of lesions, distribution, size of ground glass opacities (GGO), pure GGO, GGO with reticular and/or interlobular

septal thickening, GGO with consolidation, vascular enlargement in lesion, air bronchogram in lesion, “tree-in-bud” opacity, centrilobular nodules, bronchial wall thickening in lesion, bronchiectasis in lesion, adjacent pleural thickening, and thoracic lymphadenopathy were included. Ground glass opacity was defined as hazy increased attenuation of the lung with preservation of bronchial and vascular margins. Consolidation was considered as lesions in which broncho-vascular structures were obscured. Lesion distribution was classified as peripheral and central distribution. The size of GGO was measured in maximal dimension of the largest lesion on the transverse plane. The optimal cut-off value for the size of GGO was 4.0 cm. Thoracic lymphadenopathy was considered present if the short-axis diameter of lymph node was larger than 1 cm.

Statistical analysis was done to determine the predictive value of the CT and clinical features. The patients were categorised into 2 groups: Group 1 with COVID-19 pneumonia and group 2 with the common viral pneumonia. The CT imaging features included for analysis were: Lung involvement (single or bilateral), number of lesions (single or multiple), distribution (peripheral or central), size of GGO ( $\geq 4.0$  cm or  $< 4.0$  cm), pure GGO (absent or present), GGO with reticular and/or interlobular septal thickening (absent or present), GGO with consolidation (absent or present), vascular enlargement in lesion (absent or present), air bronchogram in lesion (absent or present), bronchiectasis in lesion (absent or present), bronchial wall thickening in lesion (absent or present), “tree-in-bud” opacity (absent or present), centrilobular nodules (absent



Figure 1: CT images of patients with COVID-19 pneumonia in bilateral lung. Axial thin-section CT images show multiple lesions of pure GGO, GGO with consolidation, GGO with reticular and/or interlobular septal thickening, and air bronchogram (arrow) in lesion.

Table 1: Clinical characteristics and univariate analyses of two groups

Characteristics	Group 1 (n=21)		Group 2 (n=16)		p value
	No. of patients	%	No. of patients	%	
<b>Sex</b>					
Male	13	62	10	62.5	0.970
Female	8	38	6	37.5	
<b>Age (Years)*</b>	48.54±14.63		41.52±23.61		0.274
<b>Fever</b>					
Present	16	76.19	14	87.5	0.384
Absent	5	23.81	2	12.5	
<b>Stuffy or runny nose</b>					
Present	2	9.5	6	37.5	0.040
Absent	19	90.5	10	62.5	
<b>Headache</b>					
Present	3	14.3	2	87.5	0.875
Absent	18	85.7	14	12.5	
<b>Sore throat</b>					
Present	3	14.3	3	18.75	0.627
Absent	18	85.7	13	81.25	
<b>Fatigue</b>					
Present	2	9.5	1	6.25	0.712
Absent	19	90.5	15	93.75	
<b>Myalgia</b>					
Present	4	19	3	18.75	0.982
Absent	17	81	13	81.25	
<b>Dry cough</b>					
Present	7	33.3	6	37.5	0.793
Absent	14	66.7	10	62.5	
<b>WBC (10<sup>3</sup>/L)*</b>	5.65±1.96		7.06±3.49		0.128
<b>Lymphocytes (10<sup>3</sup>/L) *</b>	1.54±.96		1.54±1.03		1.000

\*Mean ± SD



Figure 2: CT features of two groups.

or present), and thoracic lymphadenopathy (absent or present).

The clinical data were classified as fever (absent or present), dry cough (absent or present), stuffy or runny nose (absent or present), headache (absent or present), sore throat (absent or present), fatigue (absent or present), and

myalgia (absent or present).

Univariate analysis was applied to compare the variables of these imaging findings and the clinical data between the two groups was compared using  $\chi^2$  test, or Fisher exact test, or t test. Variables with p value less than 0.05 as determined by the multinomial logistic regression analysis

**Table 2: CT features and univariate analyses of two groups**

CT features	Group 1 (n=21)		Group 2 (n=16)		p value
	No. of patients	%	No. of patients	%	
<b>Lung involvement</b>					
<b>Single</b>	8	38	8	50	0.468
<b>Bilateral</b>	13	62	8	50	
<b>No of lesions</b>					
<b>Single</b>	5	23.8	4	25	0.933
<b>Multiple</b>	16	76.2	12	75	
<b>Distribution</b>					
<b>Peripheral</b>	19	90.5	11	68.75	0.0946
<b>Central</b>	2	9.5	5	31.25	
<b>Size of GGO</b>					
<b>≥ 4.0 cm</b>	16	71.5	4	25	0.002
<b>&lt; 4.0 cm</b>	5	28.5	12	75	
<b>GGO with reticular and/ or interlobular septal thickening</b>					
<b>Present</b>	17	81	3	18.75	0.0001
<b>Absent</b>	4	19	13	81.25	
<b>Thoracic Lymphadenopathy</b>					
<b>Present</b>	1	4.76	2	12.5	0.393
<b>Absent</b>	20	95.24	14	87.5	
<b>GGO with Consolidation</b>					
<b>Present</b>	10	47.6	7	43.75	0.815
<b>Absent</b>	11	52.4	9	56.25	
<b>Vascular Enlargement</b>					
<b>Present</b>	15	71.5	2	12.5	0.0003
<b>Absent</b>	6	28.5	14	87.5	
<b>Air Bronchogram</b>					
<b>Present</b>	10	47.6	6	37.5	0.539
<b>Absent</b>	11	52.4	10	62.5	
<b>Bronchiectasis</b>					
<b>Present</b>	4	19	1	6.67	0.260
<b>Absent</b>	17	81	15	93.33	
<b>Bronchial Wall Thickening</b>					
<b>Present</b>	3	14.3	5	31.25	0.214
<b>Absent</b>	18	85.7	11	68.75	
<b>Bronchiectasis</b>					
<b>Present</b>	4	19	1	6.67	0.260
<b>Absent</b>	17	81	15	93.33	
<b>"Tree-in-bud" opacity</b>					
<b>Present</b>	2	9.5	6	37.5	0.040
<b>Absent</b>	19	90.5	10	62.5	
<b>Centrilobular Nodules</b>					
<b>Present</b>	3	14.3	7	43.75	0.0456
<b>Absent</b>	18	85.7	9	56.25	

were chosen as the independent predictor for diagnosis of COVID-19 pneumonia. Odds ratios (OR) as estimates of relative risk with 95% confidence intervals (CI) were obtained for each risk factor. Two sided p value of less than 0.05 was considered statistically significant. Moreover, ROC curve analysis was used to evaluate the multinomial logistic regression model.

## RESULTS

Clinical and laboratory findings of all patients with COVID-19 pneumonia and common viral pneumonia are listed in table 1. Stuffy or runny nose were found to be associated with group 2 and the other clinical manifestations had no significant difference between the 2 groups. There was no significant difference in age, sex, laboratory



data distribution between both the groups.

**Imaging features:** CT findings of COVID-19 pneumonia and common viral pneumonia are summarized in table 2. Computed tomography findings including size of GGO, GGO with reticular and/or interlobular septal thickening, “tree-in-bud” opacity, centrilobular nodules, and vascular enlargement in lesion were found to be associated with group 2 patients of pneumonia. However, there was no significant difference in lung involvement, number of lesions, distribution, pure GGO, GGO with consolidation, air bronchogram in lesion, bronchiectasis in lesion, bronchial wall thickening in lesion, adjacent pleural thickening and thoracic lymphadenopathy between both the groups of viral pneumonia.

## DISCUSSION

Clinically, common symptoms at the onset of COVID-19 were fever, cough, and fatigue.<sup>6,10</sup> Patients with epidemiological risk and clinical features including fever, imaging features of pneumonia, normal or reduced WBC, or reduced lymphocytes in early stages of the disease onset can be suspected COVID-19.<sup>5,15</sup> In the present study, COVID-19 pneumonia was characterized by a fewer frequency of stuffy or runny nose, compared with other viral pneumonia. The most common imaging findings of COVID-19 pneumonia were bilateral lung involvement, multiple lesions, peripheral distribution, pure GGO, GGO with reticular and/or interlobular septal thickening, and GGO with consolidation.<sup>11,12,16,17</sup>

The other viruses usually appear as multifocal patchy consolidation with GGO on chest CT, and centrilobular nodules, bronchial wall thickening, tree-in-bud opacities are also noticed.<sup>18,19</sup> Moreover, multifocal GGO findings suggested viral pneumonia.<sup>19</sup> Results demonstrated that bilateral lung involvement, number of lesions, distribution, pure GGO, GGO with consolidation, air bronchogram in lesion, bronchiectasis in lesion, bronchial wall thickening, adjacent pleural thickening, and thoracic lymphadenopathy have no significant difference between the two groups of viral pneumonia.<sup>20,21,22</sup>

However, GGO was 4.0 cm or greater, GGO with reticular and/or interlobular septal thickening, “tree-in-bud” opacity, centrilobular nodules, vascular enlargement in lesion were found to be associated with group 2 in univariate analysis. Compared with common viral pneumonia, COVID-19 pneumonia was more likely to have GGO of 4.0 cm or greater, GGO with reticular and/or

interlobular septal thickening, and vascular enlargement in lesion, while lack “tree-in-bud” opacity and centrilobular nodules.

## CONCLUSION

GGO with reticular and/or interlobular septal thickening, absence of centrilobular nodules on computed tomography, and absence of stuffy or runny nose are presented in patients with COVID-19 pneumonia.

## REFERENCES

1. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses a statement of the Coronavirus study group. *bioRxiv*. 2020. <https://doi.org/10.1101/2020.02.07.93786> 2. 2020. Accessed 20 March 2020.
2. WHO. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. <https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020>. 2020. Accessed 20 March 2020.
3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus infected pneumonia. *N Engl J Med*. 2020;382: 1199-207.
4. Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. *World J Pediatr*. 2020; 16: 240-46.
5. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al, for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). *Mil Med Res*. 2020;7 (1):4. doi:10.1186/s40779-020-0233-6.
6. Wang D, Hu B, Hu C, Zou F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus infected pneumonia in Wuhan, China. *JAMA*. 2020;323: 1061-69.
7. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: The mystery and the miracle. *J Med Virol*. 2020; 92:401-02.
8. Hui DS, I Azhar E, Madani TA, Drostan C, Zumia A, Peterson E, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health the latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect*

- Dis.* 2020;91:264-66.
9. Chen N, Zhou M, Dong X, Qu J, Gong F, Hon Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel corona-virus pneumonia in Wuhan, China: A descriptive study. *Lancet.* 2020;395:507-13.
  10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395:497-506.
  11. Song F, Shi N, Shan F, Zhong Z, Shen J, La H, et al. Emerging 2019 novel corona-virus (2019-nCoV) pneumonia. *Radiology.* 2020;295:210-17.
  12. Chung M, Bernheim A, Mei X, Zhong M, Huang M, Zing X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). *Radiology.* 2020;295:202-07.
  13. Lei J, Li J, Li X, Qi X. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. *Radiology.* 2020;295:18.
  14. Shi H, Han X, Zheng C. Evolution of CT manifestations in a patient recovered from 2019 novel coronavirus (2019-nCoV) pneumonia in Wuhan, China. *Radiology.* 2020;295:20.
  15. Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). *Int J Surg.* 2020;76:71-76.
  16. Xu X, Yu C, Qu J, Zhang L, Jiang DH, Chen B, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. *Eur J Nucl Med Mol Imaging.* 2020;47:1275-80.
  17. Kanne JP. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: key points for the radiologist. *Radiology.* 2020;295:16-17.
  18. Koo HJ, Lim S, Choe J, Choi SH, Sung H, Do KH. Radiographic and CT features of viral pneumonia. *Radiographics.* 2018;38:719-39.
  19. Shiley KT, Van Deerlin VM, Miller WT Jr. Chest CT features of community-acquired respiratory viral infections in adult inpatients with lower respiratory tract infections. *J Thorac Imaging.* 2010;25:68-75.
  20. Chong S, Kim TS, Cho EY. Herpes simplex virus pneumonia: high-resolution CT findings. *Br J Radiol.* 2010;83:585-89.
  21. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zheng C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med.* 2020;8:420-22.
  22. Luo L, Luo Z, Jia Y, Zhou C, Ha J, Lya J, et al. CT differential diagnosis of COVID-19 and non-COVID-19 in symptomatic suspects: A practical scoring method. *BMC Pulmonary Medicine.* 2020;20:129.

### **Corresponding Author**

Dr Suresh Jat, Resident, Department of Radiodiagnosis, JLN Medical College, Ajmer, Rajasthan, India.  
email: dr.sureshjat83@gmail.com